{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-095155","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.202582+00:00","generated_at":"2026-06-07T14:18:08.811048+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aditxt to acquire Evofem in stock merger; assumes ~$100M debt, targets women's health market","bullets":["Evofem shareholders to receive 610K shares of Aditxt common and 2,327 shares of Series A-1 preferred.","Aditxt assumes ~$100M senior indebtedness; issues $5M Jan 2024 secured notes, $8M Sep 2024 secured notes, $5M unsecured notes.","Evofem's Phexxi net sales $13.4M for first 9 months 2023; non-hormonal contraceptive market projected $27.7B to $52.2B by 2031.","Closing requires shareholder approvals, SEC S-4 effectiveness, Nasdaq compliance, and warrant/note holder agreements.","Aditxt must provide $3M loan to Evofem by Jan 31, 2024; deal may be terminated if not closed by May 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-095155","json":"https://secwatch.observer/filing/0001213900-23-095155.json","markdown":"https://secwatch.observer/filing/0001213900-23-095155.md","text":"https://secwatch.observer/filing/0001213900-23-095155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/ea189850-8k425_aditxtinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:18:08.811048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d14ef884cb9a837b96e531b1e1a83c0d73a8f4b3","claim":"Aditxt, Inc. incurred senior notes.","evidence_excerpt":"Reference is made to the disclosure under Item 1.01 above with respect to the December 2023 Secured Notes, September 2024 Secured Notes and the Royalty Note","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm","confidence":0.7,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"35e8524a9cc34328f5b05b864fb0cfdb26a70113","claim":"Aditxt, Inc. entered into Agreement and Plan of Merger with Evofem Biosciences, Inc. valued at Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023 (the \" Execution Date \"), Aditxt, Inc., a Delaware corporation (the \" Company \") entered into an Agreement and Plan of Merger (the \" Merger Agreement \") with Adicure, Inc., a Delaware corporation and wholly owned subsidiary of the Company (\" Merger Sub \") and Evofem Biosciences, Inc., a Delaware corporation (\" Evofem \"), pursuant to which, Merger Sub will be merged into and with Evofem (the \" Merger \"), with Evofem surviving the Merger as a wholly owned subsidiary of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390023095155/0001213900-23-095155-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Evofem Biosciences, Inc."},{"label":"Value","value":"Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}